- Home
- NXTS vs MTNB Comparison
NXTS vs MTNB Comparison
Compare NXTS & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXTS | MTNB |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | Israel | United States |
| Employees | 9 | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.2M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NXTS | MTNB |
|---|---|---|
| Price | $2.07 | $0.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 65.0K | ★ 6.3M |
| Earning Date | 05-16-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $119,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $0.23 |
| 52 Week High | $23.80 | $3.09 |
Technical Indicators
Market Signals| Indicator | NXTS | MTNB |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 37.61 |
| Support Level | $0.55 | $0.23 |
| Resistance Level | $5.31 | $0.66 |
| Average True Range (ATR) | 0.26 | 0.06 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 34.49 | 35.44 |
Price Performance
Historical ComparisonAbout NXTS Nexentis Technologies Inc. Common Stock
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.